Targeting class I HDACs suppresses oncogenic vulnerabilities and potentiates KRAS/MAPK pathway inhibitors in KRAS-mutant cancers
Targeting class I HDACs, alone or combined with KRAS/MAPK inhibitors, represents a promising therapeutic strategy that concurrently disrupts both epigenetic and oncogenic pathways to treat KRAS-mutant cancers and overcome resistance, warranting clinical evaluation.
Authors
- Chuwei Yu
- Shangxuan Shi
- Wenzhong Yan (ORCID: https://orcid.org/0000-0003-0420-9138)
- Xiaolong Qin
- Mingyue Yao
- Chengying Xie
- Kexin Yang
- Yafang Wang
- Xiangjun Meng
- Yu Zhao
- Chengcheng Yu
- Cheng Li
- Lina Zhou
- Jianjun Cheng
Institutions
- ShanghaiTech University (CN)
- Shanghai Ninth People's Hospital (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jare.2026.02.013
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00